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doi:10.1016/j.jtcvs.2005.10.060bjective: Surgical manipulation of lung cancers may increase circulating tumor
ells and contribute to metastatic recurrence after resection. Cyclooxygenase 2 is
verexpressed in most non–small cell lung cancer and upregulates the cell adhesion
eceptor CD44. Our goal was to examine the effects of perioperative cyclooxygen-
se blockade on the metastatic potential of circulating tumor cells, CD44 expression,
nd adhesion of cancer cells to extracellular matrix.
ethods: Human non–small cell lung cancer cells (A549) were injected through the
ateral tail vein in an in vivo murine model of tumor metastasis with three random
reatment groups: no treatment, perioperative selective cyclooxygenase 2 inhibition
celecoxib) only, and continuous celecoxib. Lung metastases were assessed at 6 weeks
y a blinded observer. For in vitro experiments, cells were treated with celecoxib, and
xpression of CD44 was determined by Western blotting. Extracellular matrix adhesion
as assessed by Matrigel (BD Labware, Bedford, Mass) assay.
esults: In vivo lung metastases were significantly decreased relative to control by
oth perioperative and continuous celecoxib (P  .0135). There was no significant
ifference in number of metastases between continuous and perioperative treatment
roups. In vitro adhesion to the extracellular matrix was significantly inhibited by
elecoxib in a dose-dependent manner (P  .01). A549 cells expressed high levels
f CD44, upregulated by interleukin 1 and downregulated by celecoxib.
onclusion: Celecoxib significantly reduced establishment of metastases by circu-
ating tumor cells in a murine model. It also inhibited CD44 expression and
xtracellular matrix adhesion in vitro. Perioperative modulation of cyclooxygenase
may be a novel strategy to minimize metastases from circulating tumor cells
uring this high-risk period.
espite surgical resection of early stage non–small cell lung cancer (NSCLC),
the overall 5-year survival remains poor, with many patients having recur-
rence with distant metastases. Recurrence after surgical resection has typ-
cally been thought to be due to micrometastatic disease present at the time of
urgery. Recently, there has been a resurgence in interest in the importance of
irculating tumor cells (CTCs), the burden of which may be increased by surgical
anipulation at the time of resection.1,2 It has recently been shown that the presence
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TSf CTCs portends a poorer prognosis in patients with breast
ancer.3 Other studies have reported that approximately
0% to 48% of patients undergoing surgery for early stage
ung cancer have CTCs before surgery, and the presence of
TCs has prognostic implications.4-6 Although CTCs may
e present before surgery, it appears that surgery itself may
ncrease the burden of these cells. Yamashita and col-
eagues1 studied patient blood samples both before and after
esection for the presence of CTCs and found that 89% of
atients without preoperative CTCs had detectable tumor
ells in peripheral blood after resection. Furthermore, in a
ore recent publication, Rolle and colleagues2 reported indi-
ect evidence that these surgically induced CTCs may ulti-
ately result in established metastatic disease.
The perioperative period is a time of metastatic vulner-
bility. Typically, at the time of surgery no active systemic
ntineoplastic agents are used for fear of interfering with
urgical outcomes. Standard chemotherapy regimens, even
hen given in the neoadjuvant setting, are usually com-
leted well in advance of the planned operation. After
urgery, there is a substantial period of recovery before a
atient is considered for chemotherapy. Consequently, there
s a period of at least a month before surgery and usually 1
o 2 months afterward when the patient is devoid of sys-
emic antineoplastic agents. This perioperative period may
n fact be the time when systemic therapies should be used.
urgery and anesthesia have been shown to have immuno-
uppressive consequences.7-9 Further, many of the inflam-
atory cytokines incited by the surgical procedure may act as
rowth factors or tumor promoters. Consequently, any CTCs
resent before or induced by surgery may have a greater
hance of survival in the circulation, and thus a higher poten-
ial for establishing metastatic deposits. It seems therefore
rudent to consider antimetastatic treatment in this periop-
rative period with agents that would have little effect on
he surgical recovery of the patient.
The enzyme cyclooxygenase (COX) 2 is upregulated in
ost lung cancers and has been shown by us and others10-14
o increase tumor cell migration and invasion in vitro and to
ncrease tumor metastatic behavior in vivo. Recently, this
nzyme has also been implicated in modulating adhesion of
umor cells to extracellular matrix (ECM), a critical step in
Abbreviations and Acronyms
COX  cyclooxygenase
CTC  circulating tumor cell
ECM  extracellular matrix
IL  interleukin
NSCLC non–small cell lung cancer
Tris  tris(hydroxymethyl)aminomethanehe metastatic process. COX-2 has been shown to upregu- a
98 The Journal of Thoracic and Cardiovascular Surgery ● Auguate expression of CD44, and transfection with antisense
OX-2 RNA has been shown to decrease CD44 expres-
ion.15 CD44 is a cell surface receptor for various ECM
roteins, including a nonsulfated glucosominoglycan, hya-
uronan, known to be important in tumor cell adhesion and
nvasion.16 Hyaluronan is released by invasion of tumor
ells into the surrounding matrix and itself has been shown
o promote tumor cell motility.17,18 Furthermore, some in-
ammatory cytokines have been implicated as regulators of
ffinity of CD44 for hyaluronan, and modulation of the
ytokine response has the potential to modulate the effects
f CD44 on hyaluronan binding.19,20 Similarly, COX-2
nhibition was recently shown to downregulate the expres-
ion of the CD44 receptor in gastric cancer and to be
ssociated with impaired invasiveness.21 Blocking the ac-
ivity of this enzyme, which is further upregulated by the
nflammatory response to surgery, has the possibility of
ecreasing the metastatic potential of surgically induced
TCs. Although long-term use of many available selective
OX-2 inhibitors (especially rofecoxib and valdecoxib) has
een associated with cardiovascular side effects, these have
nly been seen with prolonged duration of treatment . De-
pite these negative side effects, the antitumor effects of
elecoxib are significant, and the drug continues to be used
n trials both alone and in combination with other modali-
ies. Further, it appears to be safe when used periopera-
ively. The medication has been used previously as an
nalgesic adjuvant in the postoperative setting and has been
hown to be safe, not interfering with the recovery of the
atient after surgery.22-24 Consequently, if celecoxib can
mpede the metastatic potential of CTCs, this approach may
e relevant as a perioperative treatment for patients under-
oing surgical resection of any cancer.
To further understand the effect of COX-2 blockade on
he metastatic potential of CTCs, we studied the effects of
elecoxib on the ability of CTCs to establish metastatic
eposits in vivo in a murine model of lung cancer metastasis
nd its impact on tumor cell–ECM adhesion and expression
f CD44 in vitro.
ethods
ells and Reagents
549 human lung adenocarcinoma cells were purchased from
merican Type Culture Collection (Manassas, Va). Cells were
ultured in Roswell Park Memorial Institute 1640 cell culture
edium supplemented with 5% fetal bovine serum (GIBCO,
arlsbad, Calif), 2-mmol/L glutamine, 100-U/mL penicillin, and
00-g/mL streptomycin, at 37°C in a 5% carbon dioxide humid-
fied incubator. Before experiments, cell viability grater than 95%
as confirmed by trypan blue staining.
n Vivo Animal Model
he University of Southern California Institutional Animal Care
nd Use Committee approved this animal study. All animals re-
st 2006
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G
TSeived humane care in compliance with the “Guide for the Care
nd Use of Laboratory Animals” (http://www.nap.edu/catalog/
140.html).
The in vivo study used a tail vein injection lung metastasis
odel. Six-week-old severe combined immunodeficient (SCID-bg)
ale mice (Harlan Sprague Dawley, Inc, Indianapolis, Ind) were
oused in polycarbonate cages (5 animals/cage) in a room lit for 12
ours each day and maintained at 27°C for 2 days before treatment.
eklad (4%) diet (Harlan Teklad, Madison, Wis) and tap water
ere provided ad libitum. Treatment diet consisted of Teklad (4%)
ixed with celecoxib at 1000 ppm. Mice were randomly assigned
o three treatment groups (n  15-16 per group): control, periop-
rative celecoxib only, and continuous celecoxib. Celecoxib ad-
inistration began 3 days before tumor cell injection for both
erioperative and continuous treatment groups. Treatment was
iscontinued on postinjection day 3 for perioperative treatment
ice and was continued for the duration of the 6-week experiment
or the continuous treatment group.
A549 cells were prepared as a suspension of 106 cells in 150 L
hosphate-buffered saline solution. Cells were injected through a
9-gauge needle into the lateral tail vein under sterile conditions.
ice were killed 6 weeks after injection, and lung metastasis was
etermined by counting the total number of neoplastic nodules
resent in the lung, as seen on the surface with a stereomicroscope
nd verified by immunohistopathologic examination by a blinded
bserver. Tumors were either snap frozen in Tissue-Tek OCT
ompound (Miles Inc, Elkhart, Ind) in a beaker of 2-isopropanol
n dry ice (18°C) or fixed in 10% neutral buffered formalin and
mbedded in paraffin.
mmunohistochemical Testing
araffin-embedded tissue sections were prepared on Superfrost
lus slides (Erie Scientific Company, Portsmouth, N.H.) at 4
mol/L. Sections were dewaxed in xylene and rehydrated in
raded alcohol baths. Citrate at pH 6.0 (Zymed Laboratories Inc,
outh San Francisco, Calif) was used for antigen retrieval. Slides
ere left for 20 minutes in this solution at 95°C and allowed to
ool to room temperature. Endogenous peroxidase was then
locked by incubation in 3% hydrogen peroxide in methanol.
onspecific mouse antigen was blocked with rabbit normal serum
Vector Laboratories, Inc, Burlingame, Calif). Endogenous avidin
nd biotin blocking was done with A/B Blocking reagents (Vector
aboratories). Primary COX-2 antibody (Cayman Chemical Com-
any, Ann Arbor, Mich), was applied at 1:100 dilution in primary
ntibody diluting buffer (Biomedia, Inc, Foster City, Calif ) at
7°C in a humid chamber for 1 hour. Detection was with a
iotinylated antirabbit secondary antibody and avidin/biotin com-
lex with horseradish peroxidase (Vector Elite ABC Kit; Vector
aboratories). The substrate used diaminobenzidine (Vector Lab-
ratories). Slides were counterstained with hematoxylin. Diluting
uffer was used as a negative control preparation. Sections of
uman distal vas deferens were used for positive control prepara-
ions. Sections were again dehydrated in graded alcohol and cov-
rslipped. Images were viewed with an Olympus BX60 micro-
cope and captured with a cooled charge-coupled device camera
Magnafire; Olympus America Inc, Melville, NY). Images were
mported into Adobe Photoshop (Adobe Systems Incorporated,
an Jose, Calif) as tagged image format files. B
The Journal of Thoracicell Adhesion Assays
549 cells were seeded onto 6-well plates at a density of 106
ells/well. After attachment overnight, cells were treated with 1%
imethyl sulfoxide or with celecoxib at 50-mol/L and 75-mol/L
oncentrations for 24 hours. Twenty-four–well cell culture plates
ere prepared by adding Matrigel ECM (BD Labware, Bedford,
ass) at 50 g/cm2 and allowed to dry overnight. The plates were
ehydrated with warm medium without serum at 37°C for 4 hours
efore adhesion experiments. After treatment, cells were harvested
nd resuspended in medium containing 5% fetal bovine serum.
ells were then added to the Matrigel-coated plates at 5  104
ells/well and allowed to attach for various times. Unattached cells
ere removed by aspiration and gentle washing with phosphate-
uffered saline solution at 15, 30, 60, and 120 minutes. Remaining
ells were fixed with formalin and stained with hematoxylin.
ttached cells were quantitated with light microscopy in 8 random
igh-power fields.
estern Blot
549 cells were seeded at density of 106 cells/well in 12-well
lates with medium containing 5% fetal bovine serum and
llowed to attach overnight. Cells were then washed in phos-
hate-buffered saline solution and subjected to the following
reatments for 24 hours: 1% dimethyl sulfoxide, interleukin (IL)
 (10 ng/mL), celecoxib at 50 mol/L, celecoxib at 75
mol/L, IL-1 plus celecoxib at 50 mol/L, and IL-1 plus
elecoxib at 75 mol/L. Cell pellets were lysed, and a protein
ssay was performed with Bio-Rad DC protein assay kit (Bio-
ad Laboratories Inc, Hercules, Calif). Protein samples were
ixed with equal volumes of tris(hydroxymethyl)aminometh-
ne (Tris)– glycine sodium dodecylsulfate loading buffer (In-
itrogen Corporation, Carlsbad, Calif), heated at 90°C for 2
inutes, and loaded onto 8% to 16% Tris-glycine ready gels
Invitrogen) at 15 g/lane. Sodium dodecylsulfate–polyacryl-
mide gel electrophoresis was performed at 125 V for 90
inutes, and protein was transferred onto polyvinylidene fluo-
ide membranes at 25 V for 90 minutes. Membranes were
ashed and blocked overnight at 4°C with 5% nonfat dry milk
n Tris-buffered saline solution with 0.1% polysorbate. Mouse
ntihuman CD44 antibody (Abcam Inc, Cambridge, Mass) at
:1000 and anti–-actin antibody at 1:5000 (Santa Cruz Bio-
echnology, Inc, Santa Cruz, Calif) were applied to the mem-
ranes for 1 hour at 37°C. After washing, blots were incubated
ith horseradish peroxidase–linked antimouse IgG conjugate
GE Healthcare Technologies, Waukesha, Wis) at 1:5000 for 1
our at room temperature. Antibody complexes were visualized
ith enhanced chemiluminescence (GE Healthcare Technolo-
ies). Blots were scanned with Fluorochem 8900 (Alpha Inno-
ech Corporation, San Leandro, Calif), AlphaEase imaging soft-
are (version 5.0; Alpha Innotech), and Adobe Photoshop
oftware (version 6.0; Adobe).
tatistical Analysis
n vitro cell adhesion experiments were performed in duplicate.
ata for both in vitro and in vivo experiments are expressed as
ean  SD unless otherwise indicated. Analysis of variance
ith one between factor and repeated measures followed by the
onferroni multiple comparison adjustment was performed for
and Cardiovascular Surgery ● Volume 132, Number 2 299
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G
TSoth in vitro and in vivo experiments. The significance of the
nteraction between time and treatment group was used to
etermine the statistical significance with time between treat-
ents in the cell adhesion experiment. We also tested the
ignificance of the slope with time within each group by means
Figure 1. Tumor metastasis in murine model. A, Mean
counted by a blinded observer, for each group. Aster
depicting surface tumor nodules for control (A1), per
groups at 6 weeks from injection. C, Histologic exam
chemical counterstain shows tumor nodules within lun
and continuous treatment (A3) groups. COX-2 stains are
continued expression of protein despite COX-2 inhib
predictably affect either messenger RNA or transcriptf regression analysis. h
00 The Journal of Thoracic and Cardiovascular Surgery ● Auguesults
xperimental Tumor Metastasis
ice treated with continuous celecoxib demonstrated a
ean of 33  60 tumor metastases, whereas control mice
rs) and SDs (error bars) of number of tumor foci, as
dicates P < .05 versus control. B, Gross specimens
rative treatment (A2), and continuous treatment (A3)
n (hematoxylin and eosin) with COX-2 immunohisto-
enchyma for control (A1), perioperative treatment (A2),
n to illustrate tumor nodules more clearly and to show
. COX-2 inhibitors are enzyme blockers and do not
f protein.s (ba
isk in
iope
inatio
g par
show
ition
ion oad a mean of 188  220 tumor metastases. Mice treated
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G
TSith perioperative celecoxib also demonstrated decreased
umor nodules, with a mean of 55  87 foci (Figure 1, A and
). This difference treatment and control groups was statis-
ically significant (P  .0135). The clinical difference be-
ween treatment groups did not reach statistical significance,
owever, when examined by single treatment group com-
arisons. The results of gross examination were confirmed
y immunohistochemical staining for COX-2 on serial sec-
ions from selected tumor samples. The sizes of the tumor
etastases in both the perioperative and continuous groups
ere also smaller than that in the control group (Figure 1, C).
n Vitro Assays
dhesion assays were performed to asses effects of celecoxib
n cell-ECM adhesion. After transient exposure of cells to
elecoxib at 50 mol/L and 75 mol/L, cells demonstrated
arkedly decreased cell-ECM adhesion relative to un-
reated control cells (P  .01; Figure 2). The effects on cell
dhesion did not improve with time during the course of the
xperiment.
Because a fundamental step in the metastatic process is
umor cell attachment to a secondary site and subsequent
nvasion, we examined the CD44 cell surface receptor,
hich is implicated in tumor cell adhesion to the extracel-
ular ligand hyaluronidate and increased invasion in vitro.
ntreated A549 cells demonstrated strong expression of
D44 receptor according to Western blot. Exposure of cells to
elecoxib resulted in decreased CD44 expression, whereas
reatment with the inflammatory cytokine IL-1 led to
D44 upregulation. This stimulatory effect of IL-1 was
brogated by the addition of celecoxib (Figure 3).
iscussion
lthough surgical resection of NSCLC is intended to cure,
he resultant increase in inflammatory cytokines, decrease in
igure 2. Graph representing tumor cell adhesion to Matrigel
CM depicts decreased ability of cells to attach when treated
ith celecoxib. DMSO, Dimethyl sulfoxide; hpf, high-power field.mmunocompetence, and potential for “stirring up” CTCs r
The Journal of Thoracicay all play a role in the subsequent appearance of meta-
tatic deposits. Recent adjuvant strategies with chemother-
py for early stage disease have resulted in an improved
urvival, suggesting that early treatment of micrometastatic
isease is advantageous. However, the perioperative period
s typically a time when no systemic therapies are given, and
ften chemotherapy is delayed for a number of months
hile the patient recovers from surgery. By that time, the
nitial events in the metastatic cascade presumably would
ave already taken place. It is prudent, therefore, to reex-
mine the perioperative period as a time of vulnerability for
etastasis and an opportunity to affect metastatic progres-
ion in patients undergoing surgery for NSCLC.
The metastatic process is complex but can be looked at in
erms of multiple steps. Initially, tumor cells invade into a
ymphovascular channel and detach from the main tumor
ass. These cells then enter the circulation as CTCs and must
void immune surveillance to survive long enough to arrive at
favorable distant site, a process that may involve a chemo-
ine gradient. The concept of surgical manipulation increasing
TCs is at least 4 decades old. The no-touch technique of
olorectal cancer resection, popularized by Turnbull in the
960s and 1970s, was aimed at decreasing the shedding of
umor cells resulting from mechanical manipulation at the time
f surgery.26,27 Although techniques for detecting CTCs were
ot available 40 years ago, newer techniques of isolating rare
ells in peripheral blood are now available and are being used
o address the relevance of CTCs.
It has been surmised that only certain CTC (such as tumor
tem cells) have the potential to become metastatic deposits.28
onetheless, recent evidence obtained with newer technol-
gy to detect rare cells in the circulation supports the view
hat detection of significant numbers of CTCs is relevant
ecause it is associated with a poorer prognosis.4-6,29 Rolle
nd colleagues2 found increased CTCs in patients undergo-
ng limited resection (lobectomy) versus those undergoing
neumonectomy, suggesting that the level of CTCs is cor-
igure 3. Western blot for CD44. IL-1 increased expression of
D44. Celecoxib (Cel) decreased expression of CD44, even after
L-1 stimulation. DMSO, Dimethyl sulfoxide.elated with the extent of parenchymal manipulation. Ya-
and Cardiovascular Surgery ● Volume 132, Number 2 301
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G
TSashita and coworkers2 found that the increased surgical
anipulation associated with video-assisted thoracoscopic
esection resulted in increased CTCs after surgery. Conse-
uently a treatment that can be given around the time of
urgery that has the possibility of reducing the metastatic
otential of circulating cells may reduce the risk of recur-
ence in patients with early stage disease.
The anti-inflammatory and antineoplastic effects of cele-
oxib, combined with a favorable side effect profile, make it
n ideal candidate for perioperative therapy. Celecoxib has
een used perioperatively as an adjuvant analgesic without
etectable side effects.22-24 In the short term, it has not been
ssociated with increased cardiovascular side effects, and in
ontrast to nonspecific COX inhibitors (nonsteroidal anti-
nflammatory agents), it has little effect on either renal or
latelet function. In this study, we aimed to expand on
revious reports that COX-2 inhibition decreases tumor
rowth and metastases in vivo10,11,14 by examining the
otential benefit of perioperative exposure. Specifically, we
ypothesized that downregulation of the activity of the
OX-2 enzyme may limit the ability of CTCs to establish
etastatic deposits, perhaps through a mechanism that in-
olves tumor cell to distant site attachment and early
nvasion.
Our in vivo experiment showed a decrease in the number of
stablished pulmonary metastases in both perioperatively and
ontinuously treated mice when A549 NSCLC cells were
njected into the peripheral circulation. This finding is perhaps
ost striking when placed within the context of the doses
dministered. The effects were seen at doses of 1000 ppm of
how, which have been shown to correspond to serum levels in
he range of 9 to 11 mol/L in animal studies.14,32 This
oncentration range is well below the inhibitory concentration
f 50% for celecoxib, as well as below levels needed for
nduction of apoptosis.14,33,34 Although one must be cautious
n extrapolating directly from in vitro data to the in vivo
ituation and vice versa, the difference is significant. Despite
he lack of a statistically significant difference between mean
umber of lung metastases seen in the continuous and periop-
rative treatment groups, histologic examination revealed that
he size of established metastases was smaller in the continu-
us treatment group than in the perioperative group, suggesting
role for ongoing tumor growth inhibition with celecoxib,
resumably through other mechanisms.
A critical step in the metastatic process involves the attach-
ent of the CTC to a distant site, a process that requires tumor
ell receptors such as the CD44 receptor. This work was
nfluenced by previous studies, which have shown a strong
ssociation between COX-2 and CD44 expression. In the lung
ancer cell line A549, upregulation of COX-2 led to an in-
rease in CD44 expression, and treatment with the exogenous
ownstream product of COX-2, 16,16-dimethyl prostaglandin
2, and also to increased CD44 expression and tumor cell C
02 The Journal of Thoracic and Cardiovascular Surgery ● Augunvasion.15,35 Moreover, CD44 has been found to be a funda-
ental requirement for tumor metastasis. Weber and col-
eagues36 found that in CD44 knockout experiments with mice
hat normally produce spontaneous colon cancers and metas-
ases, the lack of CD44 expression in CD44/ mutants does
ot inhibit primary tumor formation but rather prevents the
ormation of spontaneous secondary metastases. We demon-
trated that celecoxib decreases CD44 expression in tumor
ells in vitro. Additionally, it is able to abrogate the stimulatory
ffects of the inflammatory cytokine IL-1, which is of par-
icular importance in examining the efficacy of a treatment
dministered during the proinflammatory state of the periop-
rative period. Similarly, in the adhesion assays, exposure of
elecoxib decreased the ability of these cells to adhere to
atrigel, a surrogate for ECM.
We have inferred that one of the possible mechanisms
or the decrease in established metastases may be related to
ownregulation of the CD44 receptor, with resultant de-
rease in both adhesion and subsequent invasion at a distant
ite. The metastatic process is complex, however, and many
ther mechanisms may play roles. Celecoxib has been
hown to affect the immune response, which may play a role
n the persistent viability of circulating cells.37 Further,
hanges in the metastatic site to tumor cell chemokine
radient and in stromal-tumoral interaction are also possibly
ffected, and studies addressing these issues are currently
nderway. We and others have shown that the effects of
elecoxib also interfere with the production of matrix met-
lloproteinases, and this probably plays a role in the inva-
ion of metastatic cells.37 The well-established effects on
poptosis and angiogenesis may play a role in the continued
rowth of established implants, possibly explaining the size
ifference of tumors in the perioperative and continuous
reatment groups. However, they probably do not play a role
n the initial adhesion and invasion and subsequent estab-
ishment of a metastatic deposit, as discussed previously.
There are notable shortcomings in this study. The artifi-
ially induced CTCs with a large number of cancer cells in an
mmunocompromised mouse present a very different condition
rom the rare CTCs present in the clinical setting. Although
rtificial, this model does give some insight into the ability of
elecoxib to inhibit establishment of metastatic implants,
hich may be relevant when discussing the metastatic poten-
ial of CTCs in the perioperative period. This result was pro-
ound even at relatively low doses of celecoxib, well below
ny tumoral cytotoxic effect. It would be closer to ideal to
anipulate an established mouse lung tumor surgically and
hen assess metastatic implants, but the size of the animal and
ur inability as yet to detect CTCs in very small volumes of
lood limit our ability to do such an experiment.
In conclusion, celecoxib significantly reduced establish-
ent of lung cancer metastases in an artificial model of
TCs in vivo. In vitro, celecoxib was shown to inhibit
st 2006
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G
TSD44 expression and tumor cell adhesion to ECM. Periop-
rative modulation of COX-2 may be a novel treatment
trategy to minimize metastases from CTCs during this
igh-risk period. Continuous therapy, at least until standard
hemotherapy is initiated, may provide the additional ben-
fit of suppressing ongoing tumor growth in those cells that
ave eluded other host tumor clearance mechanisms.25,30,31
We are indebted to the expert statistical assistance of Dr Linda
han.
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